A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Cardiovascular Outcomes in Participants With HFpEF and HFmrEF (Elevate-HF)
- Heart Failure With Preserved Ejection Fraction (HFpEF)
- Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
At a glance
- Phase
- Phase 3
- Study type
- Interventional
- Sponsor
- AstraZeneca
- Enrolment target
- 6,950
- Started
- 24 August 2026
- Main results due
- 3 September 2029
- Study sites
- 679
- Registry updated
- 28 September 2026
Can you take part?
- Aged 18 years and over.
- Open to any sex.
- You need the condition being studied — healthy volunteers are not accepted.
These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.
Read the full eligibility criteria
Inclusion Criteria: * Left ventricular ejection fraction (LVEF) of \> 40% within 12 months prior to screening. * Structural heart disease evidence. * HF diagnosed with New York Heart Association (NYHA) Class II-IV at the time of screening. Exclusion Criteria: * BMI \<25 kg/m² at screening. * Diabetes exclusions: * History of type 1 diabetes. * HbA1c ≥10% at screening. * Currently receiving or anticipated to receive therapeutic intervention for diabetic retinopathy and/or macular edema. * more than 1 episode of severe hypoglycemic event within 180 days prior to screening, or hypoglycemia unawareness/poor recognition. * Renal exclusions: * On a prespecified renal replacement therapy, or eGFR below a prespecified threshold at screening * Cardiovascular exclusions: * Major cardiac surgery, coronary revascularization, valvular repair/replacement, AF/AFL ablation, CRT implantation, or ICD without CRT within 90 days prior to screening, or planned after randomization. * Heart failure due to infiltrative cardiomyopathy, active myocarditis, constrictive pericarditis, cardiac tamponade, genetic hypertrophic cardiomyopathy (including obstructive), or arrhythmogenic right ventricular cardiomyopathy/dysplasia. * GI exclusions: * Clinically significant upper GI condition affecting gastric emptying, drug absorption, or safety/tolerability interpretation; chronic use of drugs directly affecting GI motility; severe disease or prior surgery. * History of acute or chronic pancreatitis. * Endocrine exclusions: * History/ family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2, or basal calcitonin ≥35 ng/L at screening.
What this study is about
In the sponsor’s own words, from the registry.
This is a Phase III, randomized, double-blind, parallel-group, placebo-controlled, multicenter study to investigate CV outcomes with elecoglipron compared with placebo, in adults with heart failure with preserved ejection fraction (HFpEF)/heart failure with mildly reduced ejection fraction (HFmrEF), irrespective of T2DM status, and who are on background dapagliflozin in addition to other background standard of care.
Study sites(679)
Research Site
Fairhope, Alabama, United States
Recruiting
Research Site
Anchorage, Alaska, United States
Not yet recruiting
Research Site
Gilbert, Arizona, United States
Not yet recruiting
Research Site
Sun City, Arizona, United States
Not yet recruiting
Research Site
Beverly Hills, California, United States
Not yet recruiting
Research Site
Huntington Beach, California, United States
Not yet recruiting
Research Site
Huntington Park, California, United States
Not yet recruiting
Research Site
Loma Linda, California, United States
Not yet recruiting
Research Site
Lomita, California, United States
Recruiting
Research Site
Mather, California, United States
Not yet recruiting
Research Site
Northridge, California, United States
Not yet recruiting
Research Site
Palo Alto, California, United States
Not yet recruiting
Research Site
Redding, California, United States
Not yet recruiting
Research Site
San Diego, California, United States
Not yet recruiting
Research Site
Tarzana, California, United States
Withdrawn
Research Site
Colorado Springs, Colorado, United States
Not yet recruiting
Research Site
New Haven, Connecticut, United States
Not yet recruiting
Research Site
Bradenton, Florida, United States
Withdrawn
Research Site
Hallandale, Florida, United States
Not yet recruiting
Research Site
Jacksonville, Florida, United States
Not yet recruiting
Research Site
Lakeland, Florida, United States
Not yet recruiting
Research Site
Miami, Florida, United States
Not yet recruiting
Research Site
Miami, Florida, United States
Not yet recruiting
Research Site
Miami, Florida, United States
Not yet recruiting
Research Site
Miami Lakes, Florida, United States
Withdrawn
Research Site
Miami Lakes, Florida, United States
Recruiting
Research Site
Ocala, Florida, United States
Not yet recruiting
Research Site
Ocoee, Florida, United States
Withdrawn
Research Site
Palmetto Bay, Florida, United States
Not yet recruiting
Research Site
Riverview, Florida, United States
Not yet recruiting
Research Site
Tampa, Florida, United States
Not yet recruiting
Research Site
Atlanta, Georgia, United States
Not yet recruiting
Research Site
Columbus, Georgia, United States
Not yet recruiting
Research Site
Tucker, Georgia, United States
Not yet recruiting
Research Site
Champaign, Illinois, United States
Withdrawn
Research Site
Chicago, Illinois, United States
Not yet recruiting
Research Site
Gurnee, Illinois, United States
Not yet recruiting
Research Site
Melrose Park, Illinois, United States
Not yet recruiting
Research Site
Moline, Illinois, United States
Not yet recruiting
Research Site
Niles, Illinois, United States
Not yet recruiting
Research Site
Rockford, Illinois, United States
Not yet recruiting
Research Site
Schaumburg, Illinois, United States
Not yet recruiting
Research Site
Winfield, Illinois, United States
Not yet recruiting
Research Site
Indianapolis, Indiana, United States
Not yet recruiting
Research Site
Waterloo, Iowa, United States
Not yet recruiting
Research Site
Leavenworth, Kansas, United States
Not yet recruiting
Research Site
Wichita, Kansas, United States
Not yet recruiting
Research Site
Owensboro, Kentucky, United States
Not yet recruiting
Research Site
Bossier City, Louisiana, United States
Not yet recruiting
Research Site
Covington, Louisiana, United States
Not yet recruiting
Research Site
Lafayette, Louisiana, United States
Not yet recruiting
Research Site
New Orleans, Louisiana, United States
Not yet recruiting
Research Site
Shreveport, Louisiana, United States
Not yet recruiting
Research Site
Zachary, Louisiana, United States
Not yet recruiting
Research Site
Annapolis, Maryland, United States
Not yet recruiting
Research Site
Baltimore, Maryland, United States
Not yet recruiting
Research Site
Lanham, Maryland, United States
Not yet recruiting
Research Site
Oxon Hill, Maryland, United States
Not yet recruiting
Research Site
Boston, Massachusetts, United States
Not yet recruiting
Research Site
Boston, Massachusetts, United States
Not yet recruiting
Showing 60 of 679 sites — filter to narrow it down. 24 of the 679 sites on this study are recruiting right now — a site can stop enrolling while the study as a whole is still open.
Source: ClinicalTrials.gov record NCT07761117. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Not the right study?
Answer three questions and see the studies recruiting near you, in plain language.
Find a study for me